This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
In Study A, bremelanotide subjects lost an average of 1.3 kg more than placebo; in Study B, those on twice-daily bremelanotide lost 1.7 kg compared to 0.9 kg for placebo.
Why it matters
These results indicate that bremelanotide could be a promising treatment for obesity, potentially aiding in weight management for women. Understanding its effects on appetite regulation may lead to better obesity interventions.
How the study worked
Two phase 1 randomized controlled trials were conducted, one with a 1:1 placebo comparison and another as a crossover trial with multiple treatment sequences.
What this study cannot tell us
The study had a small sample size and was limited to premenopausal women, which may affect the generalizability of the results.
Read the original research
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
Diabetes, obesity & metabolism, 24(6), 1084-1093
Citation
Spana, Carl; Jordan, Robert; Fischkoff, Steven. (2022). Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.. Diabetes, obesity & metabolism, 24(6), 1084-1093. https://doi.org/10.1111/dom.14672